Table 1.
FDA-approved INSTIs and formulations.
| Compound | Trade Name | Co-Formulated Compound(s) 1 | Year of Approval |
|---|---|---|---|
| Raltegravir (RAL) | Isentress | n.a. 2 | 2007 |
| Elvitegravir (EVG) | Stribild | Cobicistat 3/FTC/TDF | 2012 |
| Genvoya | Cobicistat/FTC/TAF | 2015 | |
| Dolutegravir (DTG) | Tivicay | n.a. | 2013 |
| Juluca | RPV | 2017 | |
| Dovato | 3TC | 2019 | |
| Triumeq | ABC/3TC | 2022 | |
| Bictegravir (BIC) | Biktarvy | FTC/TAF | 2018 |
| Cabotegravir (CAB) | Vocabria | n.a. | 2021 |
| Cabenuva 4 | RPV | 2021 | |
| Apretude 4 | n.a. | 2021 |
1 FTC, emtricitabine (NRTI); TDF, tenofovir disoproxil fumarate (NRTI); TAF, tenofovir alafenamide (NRTI); RPV, rilpivirine (non-nucleoside RT inhibitor); 3TC, lamivudine (NRTI); ABC, abacavir (NRTI). 2 n.a., not applicable. 3 Pharmacokinetic enhancer. 4 Extended-release injectable suspension.